References
- Takara K, Sakaeda T, Okumura K. An update on overcoming MDR-1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006;12:273–286.
- Lee CH. Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 2010;596:325–340.
- Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1084–1086.
- Thiesing JT, Jones O, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl positive cells. Blood 2000;9:3195–3199.
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
- Gorre ME, Mahammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
- Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lineswith differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanism of resistance. Blood 2000;96:1070–1079.
- Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI 571 in human leukemic cells through gene amplification. Blood 2000;95:1758–1766.
- Tipping AJ, Mahon FX, Lagarde V, Goldenman JM, Melo JV. Restoration of sensitivity to STI571 in STI571 resistant chronic myeloid leukemia cells. B1ood 2001;98:3864–3867.
- Osborn M, Hughes T. Managing imatinib resistance in chronic myeloid leukaemia. Curr Opin Hematol 2010;17:97–103.
- Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991;77:348–354.
- Takara K, Sakaeda T, Tanigawara Y, et al. Effects of 12 Ca2+ antagonists on multidrug resistance, MDR-1 mediated transport and MDR-1 mRNA expression. Eur J Pharm Sci 2002;16:159–165.
- Engi H, Hohmann J, Gang G, et al. Chemoprevention and inhibition of P-glycoprotein in cancer cells by Chinese medicinal herbs. Phytother Res 2008;22:1671–1676.
- Qian JQ. Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivatives. Acta Pharmacol Sin 2002;23:1086–1092.
- Ye ZG, Wang JH, Sun AX, et al. Poteintation of vincristine-induced apoptosis by tetrandrine, neferine and dauricine in the human mammary MCF-7 multidrug-resistant cells. Yao Xue Xue Bao 2001;36:96–99.
- Cao JG, Tang XQ, Shi SH. Multidrug resistance reversal in human gastric carcinoma cells by neferine. World J Gastroenterol 2004;10:3062–3064.
- Ai XH, Tang XQ, Liu YP, Liu HQ, Dong L. Effect of neferine on adriamycin-resistance of thermotolerant hepatocarcinoma cell line HepG2/thermotolerance. Ai Zheng 2007;26:357–360.
- Qi J, Peng H, Gu ZL, Liang ZQ, Yang CZ. Establishment of an imatinib resistant cell line K562/G01 and its characterization. Zhonghua Xue Ye Xue Za Zhi 2004;25:337–341.
- Ricardo P. Multidrug resistance retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006;13:1859–1876.
- Frame D. New strategies in controlling drug resistance. J Manag Care Pharm 2007;13(Suppl. A):S13–S17.
- Stromskaya TP, Rybalkina1 EY, Kruglov SS, et al. Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib. Biochemistry 2008;73:29–37.
- Davidson A, Dick G, Pritchard Jones K, Pinkerton R. EVE/cyclosporin (etoposide, vincristine, epirubicin with high dose cyclosporin) chemotherapy selected for multidrug resistance modulation. Eur J Cancer 2002;38:2422–2427.